Bio-Rad Laboratories, Inc. (NYSE:BIO) – Stock analysts at Jefferies Group decreased their Q3 2017 earnings per share estimates for Bio-Rad Laboratories in a report released on Monday. Jefferies Group analyst B. Couillard now forecasts that the medical research company will post earnings per share of $0.26 for the quarter, down from their previous forecast of $0.39. Jefferies Group has a “Buy” rating and a $275.00 price target on the stock. Jefferies Group also issued estimates for Bio-Rad Laboratories’ Q3 2018 earnings at $1.05 EPS.

A number of other brokerages have also recently commented on BIO. Zacks Investment Research cut Bio-Rad Laboratories from a “hold” rating to a “sell” rating in a research report on Thursday, August 10th. BidaskClub raised Bio-Rad Laboratories from a “hold” rating to a “buy” rating in a research report on Thursday, June 22nd. Wells Fargo & Company initiated coverage on Bio-Rad Laboratories in a research report on Thursday, July 13th. They set an “outperform” rating and a $250.00 price target on the stock. Deutsche Bank AG raised Bio-Rad Laboratories from a “hold” rating to a “buy” rating and dropped their price target for the company from $220.00 to $195.00 in a research report on Wednesday, June 28th. Finally, TheStreet cut Bio-Rad Laboratories from a “b” rating to a “c+” rating in a research report on Thursday, August 3rd. One research analyst has rated the stock with a hold rating and five have given a buy rating to the stock. The company has an average rating of “Buy” and an average price target of $240.00.

ILLEGAL ACTIVITY WARNING: “Q3 2017 EPS Estimates for Bio-Rad Laboratories, Inc. (BIO) Cut by Analyst” was first published by American Banking News and is the sole property of of American Banking News. If you are reading this piece on another website, it was illegally stolen and reposted in violation of US & international copyright & trademark laws. The correct version of this piece can be read at https://www.americanbankingnews.com/2017/10/11/q3-2017-eps-estimates-for-bio-rad-laboratories-inc-bio-cut-by-analyst.html.

Bio-Rad Laboratories (NYSE BIO) opened at 222.67 on Wednesday. The firm’s 50-day moving average price is $222.12 and its 200 day moving average price is $220.81. Bio-Rad Laboratories has a 52-week low of $154.89 and a 52-week high of $242.79. The company has a market cap of $6.60 billion, a PE ratio of 440.06 and a beta of 0.91.

Several hedge funds and other institutional investors have recently modified their holdings of BIO. Canada Pension Plan Investment Board purchased a new position in shares of Bio-Rad Laboratories during the 2nd quarter valued at $113,000. Pacad Investment Ltd. bought a new stake in shares of Bio-Rad Laboratories during the 2nd quarter valued at $113,000. Turner Investments LLC bought a new stake in shares of Bio-Rad Laboratories during the 2nd quarter valued at $136,000. Capital Analysts LLC bought a new stake in shares of Bio-Rad Laboratories during the 2nd quarter valued at $170,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank raised its stake in shares of Bio-Rad Laboratories by 12.4% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 815 shares of the medical research company’s stock valued at $184,000 after purchasing an additional 90 shares during the period. 62.84% of the stock is currently owned by hedge funds and other institutional investors.

In other news, EVP Michael Crowley sold 700 shares of the company’s stock in a transaction on Friday, August 11th. The stock was sold at an average price of $215.91, for a total transaction of $151,137.00. Following the transaction, the executive vice president now owns 2,060 shares of the company’s stock, valued at approximately $444,774.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 28.29% of the stock is owned by corporate insiders.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc (Bio-Rad) is a manufacturer and distributor of its life science research and clinical diagnostics products. The Company operates through two segments: Life Science and Clinical Diagnostics. It manufactures and supplies the life science research, healthcare, analytical chemistry and other markets with a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components.

Earnings History and Estimates for Bio-Rad Laboratories (NYSE:BIO)

Receive News & Ratings for Bio-Rad Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories Inc. and related companies with MarketBeat.com's FREE daily email newsletter.